AI assistant
Mural Oncology PLC — Director's Dealing 2024
Mar 4, 2024
14932_dirs_2024-03-04_15ef843f-3050-4eb6-9d1f-1c245585f11f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Mural Oncology plc (MURA)
CIK: 0001971543
Period of Report: 2024-03-01
Reporting Person: Keson-Brookes Maiken (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-01 | Ordinary Shares | A | 16800 | $0.00 | Acquired | 46007 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-01 | Stock Option (right to buy) | $5.39 | A | 31200 | Acquired | 2034-02-28 | Ordinary Shares (31200) | Direct |
Footnotes
F1: Consists of ordinary shares issuable under 16,800 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer.
F2: This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.